LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

Home・Akciju saraksts・Simulations Plus Inc

Simulations Plus Inc

Slēgts

SektorsVeselības aprūpe

16.71 -5.7

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

16.67

Max

17.53

Galvenie mērījumi
By Trading Economics
Ienākumi	3.9M 4.5M
Pārdošana	5.9M 24M
EPS	0.35
Peļņas marža	18.669
Darbinieki	212
EBITDA	4.9M 7.2M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	-9.76% downside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 13. jūl.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	107M 358M
Iepriekšējā atvēršanas cena	22.41
Iepriekšējā slēgšanas cena	16.71

Ziņu noskaņojums

By Acuity

100%

316 / 344 Rangs Healthcare

Simulations Plus Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 2. jūn. 20:30 UTC

Peļņas

Palo Alto Networks 3Q Revenue Rises as Customers Beef Up Cyber Defenses

2026. g. 2. jūn. 23:58 UTC

Tirgus saruna

Australia's Consumer Sector Expected to Be Stung by Housing Downturn -- Market Talk

2026. g. 2. jūn. 23:46 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 2. jūn. 23:46 UTC

Tirgus saruna

Nikkei May Rise as AI Demand Hopes Continue -- Market Talk

2026. g. 2. jūn. 23:41 UTC

Tirgus saruna

Oil Rises Amid Signs of U.S.-Iran Peace Talks Stalling -- Market Talk

2026. g. 2. jūn. 23:01 UTC

Iegādes, apvienošanās, pārņemšana

ACCC Says Owner of Metro Petroleum Brand to Buy the 41 Sites

2026. g. 2. jūn. 23:01 UTC

Iegādes, apvienošanās, pārņemšana

ACCC Says Ampol Must Sell 41 Retail Fuel Sites to an Approved Purchaser

2026. g. 2. jūn. 23:00 UTC

Iegādes, apvienošanās, pārņemšana

Australia's Competition Regulator Approves Ampol's Purchase of EG Australia With Conditions

2026. g. 2. jūn. 22:57 UTC

Tirgus saruna

Australian Dollar Could Fall Following 1Q GDP Data -- Market Talk

2026. g. 2. jūn. 22:50 UTC

Tirgus saruna

Ulta Beauty Says TikTok Shop Will Provide 'Halo' Effect -- Market Talk

2026. g. 2. jūn. 21:07 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 2. jūn. 21:07 UTC

Tirgus saruna

Tokenized Assets Need Access to Digital-Finance Plumbing -- Market Talk

2026. g. 2. jūn. 21:00 UTC

Peļņas

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2026. g. 2. jūn. 20:50 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2026. g. 2. jūn. 20:46 UTC

Peļņas

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2026. g. 2. jūn. 20:38 UTC

Peļņas

GitLab Stock Rises as the Software Company Raises Guidance on AI Business Momentum -- Barrons.com

2026. g. 2. jūn. 20:21 UTC

Peļņas

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2026. g. 2. jūn. 20:12 UTC

Peļņas

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2026. g. 2. jūn. 20:05 UTC

Peļņas

Palo Alto Networks 3Q Product Rev $594M

2026. g. 2. jūn. 20:05 UTC

Peļņas

Palo Alto Networks Sees FY26 Next-Generation Security ARR $8.9B-$8.95B

2026. g. 2. jūn. 20:05 UTC

Peļņas

Palo Alto Networks Raises FY26 View To Adj EPS $3.77-Adj EPS $3.79 >PANW

2026. g. 2. jūn. 20:05 UTC

Peļņas

Palo Alto Networks 3Q Subscription and Support Rev $2.41B

2026. g. 2. jūn. 20:05 UTC

Peļņas

Palo Alto Networks Sees FY26 Remaining Performance Obligation $20.9B-$21B

2026. g. 2. jūn. 20:05 UTC

Peļņas

Palo Alto Networks Sees 4Q Rev $3.345B-$3.355B >PANW

2026. g. 2. jūn. 20:05 UTC

Peļņas

Palo Alto Networks Sees 4Q Adj EPS 96c-Adj EPS 98c >PANW

2026. g. 2. jūn. 20:05 UTC

Peļņas

Palo Alto Networks on Track to Achieve 40% Adj Free Cash Flow Margin in FY28

2026. g. 2. jūn. 20:05 UTC

Peļņas

Palo Alto Networks Raises FY26 View To Rev $11.415B-$11.425B >PANW

2026. g. 2. jūn. 20:05 UTC

Peļņas

Palo Alto Networks 3Q Remaining Performance Obligation $18.4B

2026. g. 2. jūn. 20:05 UTC

Peļņas

Palo Alto Networks 3Q Adj EPS 85c >PANW

2026. g. 2. jūn. 20:05 UTC

Peļņas

Palo Alto Networks 3Q Loss $177M >PANW

Salīdzinājums

Cenas izmaiņa

Simulations Plus Inc Prognoze

Cenas mērķis

By TipRanks

-9.76% uz leju

Prognoze 12 mēnešiem

Vidējais 16 USD -9.76%

Augstākais 16 USD

Zemākais 16 USD

Pamatojoties uz 3 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Simulations Plus Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

3 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 3 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Simulations Plus Inc — pēdējo 3 mēnešu laikā.

Noskaņojums

By Acuity

316 / 344 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.